Competition & Peer Data API & CSV Delivery Connect to AI Assistant via MCP

Q32 Bio Inc's Competitiveness

Name: Q32 Bio Inc Competitors and Peer Comparison
Creator: CSIMarket
License: https://csimarket.com/help/terms-of-use

A competitive positioning analysis and financial ratio benchmarking of Q32 Bio Inc (QTTB) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.

Peer Data As of Q2 2026

API endpoints for this dataset

                        https://api.csimarket.com/api/v1/companies/QTTB/competitors                    

                        https://api.csimarket.com/api/v1/companies/QTTB/relationships                    

                        https://api.csimarket.com/api/v1/companies/QTTB/similar                    

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

What's Included in the Financial API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

AI Integration via MCP

Connect Claude, ChatGPT, or any MCP-compatible AI assistant directly to this data.

Q32 Bio Inc's Competitor Quality Breadth

Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).

Entity	Profitable	Expanding	Above Industry Growth	Distressed
Q32 Bio Inc	-	-	-	No
High-Confidence Competitors (7)
Similar-Size Competitors (10)

Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.

QTTB Stock Performance relative to its Competitors

QTTB Competitors (weighted) Percent change over the selected range

Q32 Bio Inc's Share Price Performance vs Peer Groups

Trailing 12-month total share price return, and the share of each group that outperformed the U.S.A. 500 over the same period. Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC.

High-Confidence
(1 of 6)

Similar-Size
(4 of 10)

Entity	TTM Share Price Return (group: median)	vs U.S.A. 500
Q32 Bio Inc	159.30 %	Outperformed
Competitors combined (0)	40.4%	63.2%
High-Confidence Competitors (6)	40.4%	63.2%
Similar-Size Competitors (10)	40.4%	63.2%
Similar Growth & Profitability (0)	40.4%	63.2%

Peer Group Share Price Returns

TTM share price return and U.S.A. 500 outperformance for Q32 Bio Inc's competitor groups requires a Commercial License.

Unlock Full Access

Source: CSIMarket API (daily market-structure computation). Outperformance is trailing-12-month total return vs the U.S.A. 500 over the same window, not risk-adjusted.

QTTB Stock Performance relative to High-Confidence Competitors

QTTB High-Confidence Competitors (equal-weighted, 7) Percent change over the selected range

QTTB Stock Performance relative to Similar-Size Competitors

QTTB Similar-Size Competitors (equal-weighted, 10) Percent change over the selected range

Q32 Bio Inc's Comment on Competition and Industry Peers

The company operates in a highly competitive biopharmaceutical sector focused on developing treatments for autoimmune and inflammatory diseases. Competition arises from pharmaceutical and biotechnology companies, academic institutions, and government agencies. Key competitive factors include drug efficacy, safety, tolerability, dosing convenience, pricing, insurance coverage, reimbursement, and public perception. Success depends on completing clinical trials, securing regulatory approvals, and effective commercialization. Many competitors, including Akebia, possess greater financial, technical, and human resources, as well as more extensive experience in drug discovery, development, regulatory processes, and marketing. Industry mergers and acquisitions may further intensify competition.

Competitor data is not yet available for Q32 Bio Inc.

Q32 Bio Inc's Competitors Named by the Company

Competitive relationships identified from Q32 Bio Inc reports and corroborating sources, each with a basis and confidence.

Competitor	Basis	Confidence	Active	Sources
Akebia	Company report	85%	2022 to 2026	3
BioMarin	Company report	85%	2022 to 2026	3
Sangamo Therapeutics	Company report	85%	2022 to 2026	3
Nestlé Health Science	Company report	85%	2022 to 2026	3
Generation Bio	Company report	85%	2022 to 2026	3
Synlogic	Company report	85%	2022 to 2026	3
American Gene Technologies	Company report	85%	2022 to 2026	3
PTC Therapeutics	Company report	85%	2022 to 2026	3
Moderna	Company report	85%	2022 to 2026	3

Competitor Evidence Detail

Company report basis, confidence, active dates and source counts for Q32 Bio Inc's named competitors require a Commercial License.

Unlock Full Access

Methodology: relationships are extracted from Q32 Bio Inc reports (named-competitor disclosures) and corroborating sources. Confidence reflects evidence strength.